Paola Allavena

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5600926/publications.pdf

Version: 2024-02-01

225	52,636	4955 84	2743 192
papers	citations	h-index	g-index

227	227	227	59197
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cancer-related inflammation. Nature, 2008, 454, 436-444.	13.7	9,279
2	The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology, 2004, 25, 677-686.	2.9	5,272
3	Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 2002, 23, 549-555.	2.9	4,494
4	Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology, 2017, 14, 399-416.	12.5	2,667
5	Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 2009, 30, 1073-1081.	1.3	2,335
6	Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s. Journal of Experimental Medicine, 1998, 187, 129-134.	4.2	1,948
7	Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. European Journal of Cancer, 2006, 42, 717-727.	1.3	1,284
8	Macrophage polarization in tumour progression. Seminars in Cancer Biology, 2008, 18, 349-355.	4.3	1,026
9	Differential Expression and Regulation of Toll-Like Receptors (TLR) in Human Leukocytes: Selective Expression of TLR3 in Dendritic Cells. Journal of Immunology, 2000, 164, 5998-6004.	0.4	946
10	The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Critical Reviews in Oncology/Hematology, 2008, 66, 1-9.	2.0	866
11	Role of tumor-associated macrophages in tumor progression and invasion. Cancer and Metastasis Reviews, 2006, 25, 315-322.	2.7	789
12	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. Cancer Cell, 2013, 23, 249-262.	7.7	721
13	Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nature Immunology, 2005, 6, 507-514.	7.0	719
14	The Yinâ€Yang of tumorâ€associated macrophages in neoplastic progression and immune surveillance. Immunological Reviews, 2008, 222, 155-161.	2.8	573
15	Vitamin D3 Affects Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic Cells. Journal of Immunology, 2000, 164, 4443-4451.	0.4	572
16	Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood, 2005, 106, 419-427.	0.6	544
17	The interaction of anticancer therapies with tumor-associated macrophages. Journal of Experimental Medicine, 2015, 212, 435-445.	4.2	507
18	Cancer related inflammation: The macrophage connection. Cancer Letters, 2008, 267, 204-215.	3.2	499

#	Article	IF	Citations
19	Macrophage polarization in pathology. Cellular and Molecular Life Sciences, 2015, 72, 4111-4126.	2.4	487
20	Human Macrophageâ€“derived Chemokine (MDC), a Novel Chemoattractant for Monocytes, Monocyte-derived Dendritic Cells, and Natural Killer Cells. Journal of Experimental Medicine, 1997, 185, 1595-1604.	4.2	460
21	Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Seminars in Immunopathology, 2013, 35, 585-600.	2.8	447
22	IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. European Journal of Immunology, 1998, 28, 359-369.	1.6	436
23	Pathways connecting inflammation and cancer. Current Opinion in Genetics and Development, 2008, 18, 3-10.	1.5	368
24	The chemokine system in cancer biology and therapy. Cytokine and Growth Factor Reviews, 2010, 21, 27-39.	3.2	343
25	Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility. Journal of Immunology, 2010, 185, 642-652.	0.4	337
26	Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program. Journal of Immunology, 2003, 171, 4552-4560.	0.4	334
27	Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clinical and Experimental Immunology, 2012, 167, 195-205.	1.1	333
28	Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends in Immunology, 2001, 22, 328-336.	2.9	332
29	Increased Survival, Proliferation, and Migration in Metastatic Human Pancreatic Tumor Cells Expressing Functional CXCR4. Cancer Research, 2004, 64, 8420-8427.	0.4	313
30	Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14825-14830.	3.3	311
31	Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Human Immunology, 2009, 70, 325-330.	1.2	304
32	Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. European Journal of Cancer, 2004, 40, 1660-1667.	1.3	302
33	Cytokines as a key component of cancer-related inflammation. Cytokine, 2008, 43, 374-379.	1.4	292
34	Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. Journal of Clinical Investigation, 2001, 107, 1173-1181.	3.9	275
35	Induction of natural killer cell migration by monocyte chemotactic proteinâ^'1, â^'2 and â^'3. European Journal of Immunology, 1994, 24, 3233-3236.	1.6	273
36	Human Pancreatic Islets Produce and Secrete MCP-1/CCL2: Relevance in Human Islet Transplantation. Diabetes, 2002, 51, 55-65.	0.3	270

#	Article	IF	Citations
37	Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenvironment, 2011, 4, 141-154.	3.1	269
38	Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers. Clinical Cancer Research, 2014, 20, 2147-2158.	3.2	264
39	Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production. Cancer Research, 2005, 65, 2964-2971.	0.4	263
40	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. Cancer Research, 2010, 70, 2235-2244.	0.4	251
41	Dendritic cells as a major source of macrophage-derived chemokine/CCL22in vitro andin vivo. European Journal of Immunology, 2001, 31, 812-822.	1.6	246
42	Cellular and molecular pathways linking inflammation and cancer. Immunobiology, 2009, 214, 761-777.	0.8	238
43	CD3+ cells at the invasive margin of deeply invading (pT3â€“T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncology, The, 2009, 10, 877-884.	5.1	226
44	Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine and Growth Factor Reviews, 2010, 21, 77-82.	3.2	215
45	Human large granular lymphocytes are potent producers of interleukin-1. Nature, 1984, 309, 56-59.	13.7	210
46	Chemokine Receptor Expression and Function in CD4+ T Lymphocytes with Regulatory Activity. Journal of Immunology, 2001, 166, 996-1002.	0.4	209
47	Divergent Effects of Interleukin-4 and Interferon-Î³ on Macrophage-Derived Chemokine Production: An Amplification Circuit of Polarized T Helper 2 Responses. Blood, 1998, 92, 2668-2671.	0.6	200
48	Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses. Cells, 2020, 9, 46.	1.8	196
49	Identification of Biologically Active Chemokine Isoforms from Ascitic Fluid and Elevated Levels of CCL18/Pulmonary and Activation-regulated Chemokine in Ovarian Carcinoma. Journal of Biological Chemistry, 2002, 277, 24584-24593.	1.6	193
50	Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut, 2016, 65, 1710-1720.	6.1	193
51	The role of chemokines in the regulation of dendritic cell trafficking. Journal of Leukocyte Biology, 1999, 66, 1-9.	1.5	192
52	Chemokines in cancer related inflammation. Experimental Cell Research, 2011, 317, 664-673.	1.2	191
53	Inflammation and cancer: Breast cancer as a prototype. Breast, 2007, 16, 27-33.	0.9	181
54	Inflammation-mediated promotion of invasion and metastasis. Cancer and Metastasis Reviews, 2010, 29, 243-248.	2.7	177

#	Article	IF	Citations
55	Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Seminars in Cancer Biology, 2004, 14, 155-160.	4.3	174
56	Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. European Journal of Immunology, 2003, 33, 2886-2893.	1.6	173
57	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. OncoImmunology, 2016, 5, e1085147.	2.1	169
58	Molecular pathways and targets in cancer-related inflammation. Annals of Medicine, 2010, 42, 161-170.	1.5	165
59	Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clinical and Experimental Metastasis, 2007, 24, 121-130.	1.7	163
60	The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Research, 2003, 63, 7451-61.	0.4	154
61	The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma. Cancer Research, 2008, 68, 9060-9069.	0.4	153
62	Chemokines and dendritic cell traffic. Journal of Clinical Immunology, 2000, 20, 151-160.	2.0	151
63	Rapamycin impairs antigen uptake of human dendritic cells1. Transplantation, 2003, 75, 137-145.	0.5	147
64	Monocyte-derived dendritic cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally different. Blood, 2005, 106, 2818-2826.	0.6	145
65	Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction. Journal of Biological Chemistry, 1999, 274, 3988-3993.	1.6	142
66	The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunological Reviews, 2000, 177, 141-149.	2.8	139
67	Neutrophils produce biologically active macrophage inflammatory protein-3Î± (MIP-3Î±) / CCL20 and MIP-3Î² / CCL19. European Journal of Immunology, 2001, 31, 1981-1988.	1.6	139
68	Defective Expression of the Monocyte Chemotactic Protein-1 Receptor CCR2 in Macrophages Associated with Human Ovarian Carcinoma. Journal of Immunology, 2000, 164, 733-738.	0.4	136
69	Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. Journal of Leukocyte Biology, 1999, 66, 489-494.	1.5	132
70	From Pattern Recognition Receptor to Regulator of Homeostasis: The Double-Faced Macrophage Mannose Receptor. Critical Reviews in Immunology, 2004, 24, 179-192.	1.0	132
71	Papillary Carcinoma of the Thyroid. American Journal of Pathology, 2000, 156, 831-837.	1.9	131
72	Induction of Functional IL-8 Receptors by IL-4 and IL-13 in Human Monocytes. Journal of Immunology, 2000, 164, 3862-3869.	0.4	128

#	Article	IF	Citations
73	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1954-1961.	3.3	122
74	Adhesion, Transendothelial Migration, and Reverse Transmigration of In Vitro Cultured Dendritic Cells. Blood, 1998, 92, 207-214.	0.6	120
75	Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. British Journal of Cancer, 2017, 117, 628-638.	2.9	119
76	Tumor-Derived MUC1 Mucins Interact with Differentiating Monocytes and Induce IL-10highIL-12low Regulatory Dendritic Cell. Journal of Immunology, 2004, 172, 7341-7349.	0.4	115
77	Distinct Transcriptional Programs Activated by Interleukin-10 with or without Lipopolysaccharide in Dendritic Cells: Induction of the B Cell-Activating Chemokine, CXC Chemokine Ligand 13. Journal of Immunology, 2004, 172, 7031-7042.	0.4	113
78	Targeting tumor associated macrophages: The new challenge for nanomedicine. Seminars in Immunology, 2017, 34, 103-113.	2.7	110
79	Interleukin-17â€“Producing T-Helper Cells as New Potential Player Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation. Transplantation, 2009, 88, 1261-1272.	0.5	108
80	Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. International Journal of Cancer, 1980, 25, 573-582.	2.3	100
81	Tumor-associated myeloid cells: diversity and therapeutic targeting. Cellular and Molecular Immunology, 2021, 18, 566-578.	4.8	100
82	Tumor-associated macrophages and anti-tumor therapies: complex links. Cellular and Molecular Life Sciences, 2016, 73, 2411-2424.	2.4	99
83	Inflammation as target in cancer therapy. Current Opinion in Pharmacology, 2017, 35, 57-65.	1.7	91
84	Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. Journal of Neuroimmunology, 2010, 224, 39-44.	1.1	90
85	Receptors, signal transduction, and spectrum of action of monocyte chemotactic protein-1 and related chemokines. Journal of Leukocyte Biology, 1995, 57, 788-794.	1.5	86
86	The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. International Immunology, 2004, 16, 149-161.	1.8	86
87	Chapter 5 Expression of Chemokines and Chemokine Receptors in Human Colon Cancer. Methods in Enzymology, 2009, 460, 105-121.	0.4	85
88	INHIBITION OF HUMAN NATURAL KILLER ACTIVITY BY CYCLOSPORIN A. Transplantation, 1981, 31, 113-116.	0.5	82
89	Glucocorticoids increase the endocytic activity of human dendritic cells. International Immunology, 1999, 11, 1519-1526.	1.8	80
90	Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. , 2016, 4, 21.		79

#	Article	IF	Citations
91	Tumor-Associated Macrophages as Incessant Builders and Destroyers of the Cancer Stroma. Cancers, 2011, 3, 3740-3761.	1.7	73
92	Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3KÎ´/Î³ Inhibitor RP6530. Clinical Cancer Research, 2019, 25, 1098-1112.	3.2	69
93	Tertiary Intratumor Lymphoid Tissue in Colo-Rectal Cancer. Cancers, 2012, 4, 1-10.	1.7	68
94	Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment. Oncotarget, 0, 7, 41662-41676.	0.8	66
95	Autoimmunity and b-cell dysfunction in chronic proliferative disorders of large granular lymphocytes/natural killer cells. Cancer, 1989, 63, 90-95.	2.0	62
96	Differential Effects of Immunosuppressive Drugs on Chemokine Receptor CCR7 in Human Monocyte-Derived Dendritic Cells: Selective Upregulation by Rapamycin. Transplantation, 2006, 82, 826-834.	0.5	62
97	Human Adipose Tissue Macrophages Display Activation of Cancer-related Pathways. Journal of Biological Chemistry, 2012, 287, 21904-21913.	1.6	60
98	A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 236-247.	1.4	59
99	Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. International Journal of Cancer, 1989, 44, 494-500.	2.3	58
100	Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. OncoImmunology, 2018, 7, e1393596.	2.1	58
101	Targeting tumour-associated macrophages. Expert Opinion on Therapeutic Targets, 2007, 11, 1219-1229.	1.5	56
102	Soluble stromaâ€•related biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	3.3	56
103	Intestinal Epithelial Cells Control Dendritic Cell Function. Annals of the New York Academy of Sciences, 2004, 1029, 66-74.	1.8	55
104	Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. European Journal of Cancer, 2010, 46, 3383-3392.	1.3	55
105	Tumor-Associated Macrophages and Dendritic Cells as Prototypic Type II Polarized Myeloid Populations. Tumori, 2003, 89, 459-468.	0.6	54
106	Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and ZalypsisÂ® (PM00104). International Journal of Cancer, 2013, 133, 2024-2033.	2.3	54
107	Infiltration of Tumours by Macrophages and Dendritic Cells: Tumour-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes. Novartis Foundation Symposium, 2008, , 137-148.	1.2	53
108	Production of multiple cytokines by clones of human large granular lymphocytes. Cancer Immunology, Immunotherapy, 1985, 19, 121-6.	2.0	52

#	Article	IF	Citations
109	Human monocyte-derived and CD34+cell-derived dendritic cells express functional receptors for platelet activating factor. FEBS Letters, 1997, 418, 98-100.	1.3	49
110	Trabectedin. OncoImmunology, 2013, 2, e24614.	2.1	49
111	Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. International Journal of Cancer, 2016, 138, 983-991.	2.3	49
112	Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways. Toxicological Sciences, 2018, 163, 346-352.	1.4	49
113	Pharmacological modulation of monocytes and macrophages. Current Opinion in Pharmacology, 2014, 17, 38-44.	1.7	48
114	Secretome Analysis of Multiple Pancreatic Cancer Cell Lines Reveals Perturbations of Key Functional Networks. Journal of Proteome Research, 2010, 9, 4376-4392.	1.8	45
115	Mesothelial cells induce the motility of human ovarian carcinoma cells. , 1999, 80, 303-307.		44
116	Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism. Journal of Experimental and Clinical Cancer Research, 2019, 38, 208.	3.5	43
117	Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. , 2021, 9, e002408.		43
118	Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. International Immunopharmacology, 2003, 3, 189-196.	1.7	42
119	Therapeutic Manipulation of Tumor-associated Macrophages: Facts and Hopes from a Clinical and Translational Perspective. Clinical Cancer Research, 2021, 27, 3291-3297.	3.2	42
120	ORIGINAL ARTICLE: Decidual Natural Killer Cell Tuning by Autologous Dendritic Cells. American Journal of Reproductive Immunology, 2008, 59, 433-445.	1.2	41
121	Macrophage Control of Inflammation: Negative Pathways of Regulation of Inflammatory Cytokines. Novartis Foundation Symposium, 2008, 234, 120-135.	1.2	41
122	Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment. Marine Drugs, 2014, 12, 719-733.	2.2	40
123	Intraperitoneal administration ofcorynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: Effects on cytotoxicity of tumor-associated macrophages and NK cells. International Journal of Cancer, 1981, 27, 437-446.	2.3	38
124	Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumorâ€conditioned macrophages. European Journal of Immunology, 2019, 49, 801-811.	1.6	38
125	Clinical relevance of clonal hematopoiesis in persons aged â‰¥80 years. Blood, 2021, 138, 2093-2105.	0.6	37
126	Linking Inflammation Reactions to Cancer: Novel Targets for Therapeutic Strategies. Advances in Experimental Medicine and Biology, 2008, 610, 112-127.	0.8	37

#	Article	IF	Citations
127	Effects of granulocyteâ€monocyte colonyâ€stimulating factor (GMâ€CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancerâ€associated macrophages. International Journal of Cancer, 1995, 60, 300-307.	2.3	36
128	Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cellular Immunology, 1989, 120, 250-258.	1.4	35
129	The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination. Journal of Immunology, 2016, 196, 902-914.	0.4	35
130	CD40 activation of BCP-ALL cells generates IL-10â€“producing, IL-12â€“defective APCs that induce allogeneic T-cell anergy. Blood, 2004, 104, 744-751.	0.6	32
131	Heme-oxygenase-1 Production by Intestinal CX3CR1+ Macrophages Helps to Resolve Inflammation and Prevents Carcinogenesis. Cancer Research, 2017, 77, 4472-4485.	0.4	32
132	H1 variant synthesis in proliferating and quiescent human cells. FEBS Journal, 1986, 154, 273-279.	0.2	31
133	Tuning of Innate Immunity and Polarized Responses by Decoy Receptors. International Archives of Allergy and Immunology, 2003, 132, 109-115.	0.9	30
134	Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer. PLoS ONE, 2016, 11, e0148186.	1.1	30
135	Expression of lineage-restricted protein tyrosine kinase genes in human natural killer cells. European Journal of Immunology, 1991, 21, 843-846.	1.6	29
136	MAGE, BAGE and GAGE genes experiences in fresh epithelial ovarian carcinomas. , 1996, 67, 457-460.		29
137	Identification and genomic organization of a gene coding for a new member of the cell adhesion molecule family mapping to Xq25. Gene, 1998, 214, 1-6.	1.0	28
138	Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. OncoImmunology, 2018, 7, e1388485.	2.1	28
139	Macrophages and cancer stem cells: a malevolent alliance. Molecular Medicine, 2021, 27, 121.	1.9	27
140	PLGA Based Nanoparticles for the Monocyte-Mediated Anti-Tumor Drug Delivery System. Journal of Biomedical Nanotechnology, 2020, 16, 212-223.	0.5	26
141	Metabolome of Pancreatic Juice Delineates Distinct Clinical Profiles of Pancreatic Cancer and Reveals a Link between Glucose Metabolism and PD-1+ Cells. Cancer Immunology Research, 2020, 8, 493-505.	1.6	26
142	Human glioma tumors express high levels ofÂtheÂchemokine receptor CX3CR1. European Cytokine Network, 2010, 21, 27-33.	1.1	26
143	Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: Role of cell adhesion to endothelium. European Journal of Cancer, 1992, 28, 818-825.	1.3	24
144	Intestinal Macrophages at the Crossroad between Diet, Inflammation, and Cancer. International Journal of Molecular Sciences, 2020, 21, 4825.	1.8	24

#	Article	IF	Citations
145	Monocytes from Wiskott-Aldrich patients differentiate in functional mature dendritic cells with a defect in CD83 expression. European Journal of Immunology, 2001, 31, 3413-3421.	1.6	23
146	Arginine-Based Poly(I:C)-Loaded Nanocomplexes for the Polarization of Macrophages Toward M1-Antitumoral Effectors. Frontiers in Immunology, 2020, 11, 1412.	2.2	23
147	Association of large granular lymphocyte/natural killer cell proliferative disease and second hematologic malignancy. American Journal of Hematology, 1988, 29, 85-93.	2.0	21
148	Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its in vivo synergism with gemcitabine. DMM Disease Models and Mechanisms, 2016, 9, 1461-1471.	1.2	21
149	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer, 2017, 116, 335-343.	2.9	20
150	Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. Annals of Medicine, 2011, 43, 581-593.	1.5	19
151	Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thrombosis and Haemostasis, 2011, 106, 705-711.	1.8	18
152	Inhibition of tumorâ€associated macrophages by trabectedin improves the antitumor adaptive immunity in response to antiâ€PDâ€1 therapy. European Journal of Immunology, 2021, 51, 2677-2686.	1.6	18
153	Association of NK-Cell Lymphoproliferative Disease and Nephrotic Syndrome. American Journal of Clinical Pathology, 1990, 94, 334-338.	0.4	17
154	IL-4 inhibits binding and cytotoxicity of NK cells to vascular endothelium. Cytokine, 1994, 6, 135-140.	1.4	17
155	In Vitro Studies on the Trafficking of Dendritic Cells Through Endothelial Cells and Extra-Cellular Matrix. Autoimmunity, 2000, 7, 143-153.	0.6	17
156	Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 Î”icsA Î”ent Î”fep Î”stxA:HgR oral vaccine SC599 in healthy human adult volunteers. Vaccine, 2008, 26, 978-987.	1.7	17
157	Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. Cancer Immunology, Immunotherapy, 2015, 64, 83-89.	2.0	17
158	Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes. International Journal of Immunopharmacology, 1989, 11, 29-34.	1.1	16
159	Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Npj Precision Oncology, 2021, 5, 61.	2.3	16
160	The Chemokine Superfamily: Crosstalk with the IL-1 System. Immunobiology, 1996, 195, 522-549.	0.8	15
161	Monocyteâ€“macrophage polarization and recruitment pathways in the tumour microenvironment of Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 1157-1171.	1.2	15
162	Interleukinâ€1 and tumor necrosis factor production in acute nonâ€lymphoid leukemia. European Journal of Haematology, 1989, 42, 16-23.	1.1	14

#	Article	IF	Citations
163	Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System. Current Pharmaceutical Design, 2012, 18, 2432-2438.	0.9	14
164	The Role of Chemokines and their Receptors in Tumor Progression and Invasion: Potential New Targets of Biological Therapy. Current Cancer Therapy Reviews, 2005, 1, 81-92.	0.2	13
165	Tumor-associated macrophages (TAMs) as new target in anticancer therapy. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 361-366.	0.5	13
166	Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 477-484.	1.1	13
167	Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy. Disease Markers, 2018, 2018, 1-9.	0.6	13
168	Chemokines as targets for pharmacological intervention. , 1996, 47, 53-80.		12
169	Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells. Cancer Immunology, Immunotherapy, 1988, 27, 69-76.	2.0	11
170	Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability. Cancer Immunology, Immunotherapy, 2000, 49, 544-550.	2.0	11
171	Regulation of the Chemokine System at the Level of Chemokine Receptor Expression and Signaling Activity. Immunobiology, 2001, 204, 536-542.	0.8	11
172	Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists. Biomedicines, 2022, 10, 1590.	1.4	11
173	Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment. Frontiers in Oncology, 2022, 12, 851790.	1.3	10
174	DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response. Cancer Immunology, Immunotherapy, 1988, 27, 63-68.	2.0	9
175	Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells. Cancer Immunology, Immunotherapy, 1990, 32, 241-244.	2.0	9
176	New activities for the anti-tumor agent trabectedin: taking two birds with one stone. Oncotarget, 2013, 4, 496-497.	0.8	9
177	Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. International Journal of Molecular Sciences, 2022, 23, 5786.	1.8	9
178	Investigation of Chronic Lymphocytosis in Adults. American Journal of Clinical Pathology, 1988, 89, 783-787.	0.4	8
179	Vasodilation in multistep paradigm of leucocyte extravasation. Lancet, The, 1994, 343, 1499-1500.	6.3	8
180	Cells with stemness features are generated from in vitro transformed human fibroblasts. Scientific Reports, 2018, 8, 13838.	1.6	8

#	Article	IF	Citations
181	Shaping and tuning of the chemokine system by regulation of receptor expression and signaling:. Journal of Neuroimmunology, 2000, 107, 174-177.	1.1	7
182	Chemokines mRNA expression in relation to the Macrophage Migration Inhibitory Factor (MIF) mRNA and Vascular Endothelial Growth Factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: A pilot study. Cytokine, 2013, 64, 509-515.	1.4	7
183	Dendritic cells and chemokines. , 2001, , 203-211.		7
184	Inflammatory and Innate Immune Cells in Cancer Microenvironment and Progression. , 2015, , 9-28.		6
185	The Good and the Bad Side of Heme-Oxygenase-1 in the Gut. Antioxidants and Redox Signaling, 2020, 32, 1071-1079.	2.5	6
186	Commitment of juvenile myelo-monocytic (JMML) leukemic cells to spontaneously differentiate into dendritic cells. The Hematology Journal, 2002, 3, 302-310.	2.0	6
187	RAEB IN PATIENT WITH CHRONIC GRANULATED Tâ€LYMPHOCYTOSIS. British Journal of Haematology, 1987, 65, 503-504.	1.2	5
188	Chemokine receptors: interaction with HIV-1 and viral-encoded chemokines. Pharmaceutica Acta Helvetiae, 2000, 74, 305-312.	1.2	5
189	Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer. Cancers, 2022, 14, 2653.	1.7	5
190	Mechanisms of natural cell-mediated resistance in human solid tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 1986, 865, 281-288.	3.3	4
191	Mechanisms of Interleukin-2-Induced Hydrothoraxy in Mice. Journal of Immunotherapy, 1994, 15, 194-201.	1.2	4
192	MODULATION OF NK ACTIVITY BY HUMAN MONONUCLEAR PHAGOCYTES: SUPPRESSIVE ACTIVITY OF BRONCHO-ALVEOLAR MACROPHAGES. , 1982, , 581-588.		4
193	Divergent Effects of Interleukin-4 and Interferon-Î³ on Macrophage-Derived Chemokine Production: An Amplification Circuit of Polarized T Helper 2 Responses. Blood, 1998, 92, 2668-2671.	0.6	4
194	Optical in vivo imaging detection of preclinical models of gut tumors through the expression of integrin Î±VÎ²3. Oncotarget, 2018, 9, 31380-31396.	0.8	4
195	Cloned lines of SJL/J spleen cells with cytotoxic reactivity. International Journal of Cancer, 1983, 31, 345-350.	2.3	3
196	Isolation of human monocyte chemotactic proteins and study of their producer and responder cells by immunotests and bioassays. Methods in Enzymology, 1997, 287, 109-127.	0.4	3
197	Molecular links between inflammation and cancer. , 0, , 273-281.		3
198	NATURAL KILLER ACTIVITY IN HUMAN OVARIAN TUMORS. , 1982, , 1119-1126.		3

#	Article	IF	Citations
199	Immunological and genotypic analysis of human TÎ³-lymphoproliferative disorders. Research in Clinic and Laboratory, 1986, 16, 29-35.	0.3	3
200	c-fos proto-oncogene expression in human NK/LGL cells: Expression is not constitutive and is associated with functional activation. International Journal of Cancer, 1988, 42, 709-711.	2.3	2
201	Killing of Tumor Cells with Pleiotropic Drug Resistance by OK432-Activated Effector Cells. Immunopharmacology and Immunotoxicology, 1989, 11, 257-268.	1.1	2
202	Transendothelial Migration and Reverse Transmigration of In Vitro Cultured Human Dendritic Cells. , 2001, 64, 325-330.		2
203	Tumors as a Paradigm for the In Vivo Role of Chemokines in Leukocyte Recruitment. , 1999, , 35-49.		2
204	Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma. , 2019, , 69-84.		2
205	The Yin Yang of Cancer Related Inflammation. , 2011, , 11-16.		2
206	Tumor-associated Macrophages in Cancer Growth and Progression. , 2013, , 451-471.		1
207	Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy. , 2015, , 263-282.		1
208	Tumor-Associated Macrophages. , 2016, , 493-498.		1
209	Tumor-Associated Myeloid Cells in Cancer Progression. , 2020, , 29-46.		1
210	Tumor-Associated Macrophages in Cancer Growth and Progression. , 2007, , 289-307.		1
211	Tumor-Associated Macrophages. , 2014, , 425-443.		1
212	T-cell receptor gene rearrangements and expression in normal human large granular lymphocytes (LGL) and their pathological expansions. Cytotechnology, 1987, 1, 79-81.	0.7	0
213	Chemokine receptors: interaction with HIV-1 and viral-encoded chemokines. Pharmacochemistry Library, 2000, 31, 305-312.	0.1	0
214	Chemotaxis of In Vitro Cultured Human Dendritic Cells. , 2001, 64, 307-312.		0
215	Production of the Long Pentraxin PTX3 by Myeloid Dendritic Cells: Linking Cellular and Humoral Innate Immunity. , 0, , 165-174.		0
216	Tumor-Associated Macrophages. , 2011, , 3808-3812.		0

#	Article	IF	Citations
217	Cytotoxicity on Tumor Cells of Human Macrophages: Functional Status of Tumor-Associated Effector Cells. Advances in Experimental Medicine and Biology, 1982, 141, 99-108.	0.8	0
218	Chemokines: Attraction of dendritic cells and role in tumor immunobiology. , 1998, , 1-22.		0
219	Regulation of Inflammatory Cytokine Receptor Expression by Pro- and Anti-Inflammatory Molecules. , 1998, , 87-96.		0
220	Molecules Involved in the Recruitment and Regulation of Tumor-Associated Macrophages. , 1998, , 239-252.		0
221	Tumor-Associated Macrophages. , 2015, , 1-6.		0
222	Tumor-Associated Macrophages. , 2017, , 4690-4695.		0
223	Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotherapy. , 2021, , 251-271.		0
224	Trabectedin, a Drug Acting on Both Cancer Cells and the Tumor Microenvironment. Human Perspectives in Health Sciences and Technology, 2020, , 287-300.	0.2	0
225	Chemokine and Receptor Expression in Tumor Progression. , 2007, , 267-283.		0